• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    June 7, 2024 - FDA Roundup: June 7, 2024

    6/7/24 3:46:22 PM ET
    $GERN
    $SRAX
    $SNAP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Advertising
    Consumer Discretionary
    Get the next $GERN alert in real time by email
    For Immediate Release:
    June 07, 2024

    Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: 

    • Today, the FDA announced that it has advised the manufacturers of the licensed and authorized COVID-19 vaccines that the COVID-19 vaccines (2024-2025 Formula) for use in the United States should be monovalent (single strain) JN.1 vaccines to more closely match currently circulating SARS-CoV-2 viruses. This action is based on the totality of the evidence and input from Wednesday’s Vaccines and Related Biological Products Advisory Committee, which unanimously voted to recommend a monovalent JN.1-lineage vaccine composition. Following the vote, the committee discussed considerations for the selection of a specific JN.1 lineage SARS-CoV-2 strain (e.g., JN.1 or KP.2) and expressed a strong preference for JN.1. It is expected that the updated vaccines will be available this fall. 
    • On Thursday, the FDA updated the Manufacturer and User Facility Device Experience (MAUDE) database, which contains medical device reports (MDRs) of adverse events, to provide additional information to the public. To help further promote transparency, the FDA is updating the MAUDE database so search results display supplement report dates. Corresponding updates have been made to the field descriptions of MDRs on the About MAUDE Database web page. The FDA continues to seek ways to improve the MAUDE database and the availability of MDR information for the public.
    • On Thursday, the FDA approved imetelstat (Rytelo, Geron Corporation), an oligonucleotide telomerase inhibitor, for adults with low- to intermediate-1 risk Myelodysplastic Syndromes (MDS) with transfusion-dependent anemia requiring four or more red blood cell units over 8 weeks who have not responded to, have lost response to, or are ineligible for erythropoiesis-stimulating agents (ESAs). The most common adverse reactions (≥ 10% with a difference between arms of > 5% compared to placebo), including laboratory abnormalities, were decreased platelets, decreased white blood cells, decreased neutrophils, increased aspartate aminotransferase, increased alkaline phosphatase, increased alanine aminotransferase, fatigue, prolonged partial thromboplastin time, arthralgia/myalgia, COVID-19 infections, and headache. Full prescribing information for Rytelo will be posted on Drugs@FDA. 
    • On Thursday, the FDA provided an update on the status of the agency’s review of the premarket tobacco product applications (PMTAs) submitted by JUUL Labs, Inc.; The FDA rescinded marketing denial orders (MDOs) issued in June 2022 to JUUL Labs, Inc. This action was taken, in part, as a result of new case law, as well as the FDA’s review of information provided by the applicant. Rescission of the MDOs is not an authorization or a denial and does not indicate whether the applications are likely to be authorized or denied. Rescission of the MDOs returns the applications to pending status, under substantive review by the FDA. The agency’s continued review does not alter the fact that all e-cigarette products, including those made by JUUL, are required by law to have FDA authorization to be legally marketed.
    • On Wednesday, the FDA issued a safety alert, advising restaurants and retailers not to serve or sell and consumers not to eat certain shellfish from Oregon and Washington potentially contaminated with paralytic shellfish toxins.
    • On Wednesday, the FDA published a draft guidance for industry describing the processes and practices applicable to inspections of sites and facilities under FDA’s Bioresearch Monitoring (BIMO) program, as conducted in accordance with section 704(a)(5) of the Federal Food, Drug, and Cosmetic Act. Specifically, this guidance addresses matters including the types of records and information required to be provided and best practices for communication between FDA and industry. FDA is issuing this draft guidance to comply with section 3612(b)(2) of the Food and Drug Omnibus Reform Act of 2022 (FDORA), enacted as part of the Consolidated Appropriations Act, 2023. The deadline for submitting comments to the docket is August 5, 2024. 
    • On Wednesday, the FDA announced the closing date of the public comment period on Swedish Match U.S.A., Inc’s modified risk tobacco product (MRTP) renewal application for General Snus products. Public comments on these applications must be submitted to the docket by 11:59 p.m. EDT on July 5, 2024 to ensure they receive consideration by FDA. The final materials on this application have now been posted.
    • On Wednesday, the FDA issued an advisory for a multistate outbreak of Salmonella Africana infections potentially linked to cucumbers. CDC and FDA are also investigating an outbreak of Salmonella Braenderup infections, with 158 illnesses in 23 states. The two outbreaks share several similarities, including where and when illnesses occurred and the demographics of ill people. Investigators are working to determine whether the two outbreaks could be linked to the same food vehicle. Fresh Start Produce Sales, Inc. has recalled cucumbers grown in Florida and distributed to retail distribution centers, wholesalers, and food service distributors in AL, FL, GA, IL, MD, NC, NJ, NY, OH, PA, SC, TN, VA, and WV from May 17 through May 21, 2024. Although these cucumbers have resulted in a positive Salmonella sample result, the FDA has not linked these products to any ongoing outbreaks. Retailers and distributors that purchased recalled Fresh Start cucumbers should notify their customers of the recall. Retailers that have or had recalled product should clean and sanitize any areas that could have come into contact with recalled products.
    • On Tuesday, the FDA published an article in the FDA Voices series: “Join Us in Recognizing National Black Family Cancer Awareness Week,” by Richard Pazdur, M.D., Director, Oncology Center of Excellence (OCE), and Rea Blakey, Associate Director for External Outreach and Engagement, OCE. OCE invites the public to join the “4th Annual National Black Family Cancer Awareness Week, Engaging the Generations” initiative and the #BlackFamCan social media campaign this year, June 13-19, 2024. The event is virtual and open to the public. Register now for the June 13 Conversations on Cancer public panel discussion which will be live streamed from 2:30 – 4:00 p.m. ET.
    • This week the FDA presented Congress with its Report on Drug Shortages for Calendar Year 2023, the 11th annual report, to summarize major actions the agency took to prevent or mitigate drug shortages in the United States. 2023 was a challenging year for shortages as manufacturers in the U.S. and abroad continue to experience quality issues and capacity constraints. FDA also saw an additional strain on the pharmaceutical supply chain from increased demand for numerous drugs, as well as unexpected events like facility closures and natural disasters.

      Considering these challenges, the agency made a significant impact in helping to prevent or mitigate drug shortages. During CY 2023 there were 55 new shortages (33 drug shortages handled by the Center for Drug Evaluation and Research, and 22 biological product shortages handled by the Center for Biologics Evaluation and Research), and the FDA helped prevent 236 shortages.

    Related Information

    Related Information
    • FDA Newsroom

    ###

    Boilerplate

    The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, radiation-emitting electronic products, and for regulating tobacco products.


    Inquiries

    Media:
    FDA Office of Media Affairs
    888-INFO-FDA
    Consumer:
    888-INFO-FDA

     
    Get the next $GERN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GERN
    $SRAX
    $SNAP

    CompanyDatePrice TargetRatingAnalyst
    Geron Corporation
    $GERN
    5/8/2025$1.50Sector Outperform → Sector Perform
    Scotiabank
    Geron Corporation
    $GERN
    2/27/2025$3.50 → $2.00Buy → Neutral
    B. Riley Securities
    Geron Corporation
    $GERN
    2/26/2025Buy → Neutral
    H.C. Wainwright
    Snap Inc.
    $SNAP
    2/11/2025Buy → Neutral
    Guggenheim
    Snap Inc.
    $SNAP
    2/5/2025Overweight
    Barclays
    Snap Inc.
    $SNAP
    2/5/2025$15.00 → $11.00Overweight → Equal Weight
    Wells Fargo
    Geron Corporation
    $GERN
    11/5/2024$8.00Buy
    H.C. Wainwright
    Snap Inc.
    $SNAP
    10/23/2024$17.00Mkt Perform → Mkt Outperform
    JMP Securities
    More analyst ratings

    $GERN
    $SRAX
    $SNAP
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • June 7, 2024 - FDA Roundup: June 7, 2024

      For Immediate Release: June 07, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced that it has advised the manufacturers of the licensed and authorized COVID-19 vaccines that the COVID-19 vaccines (2024-2025 Formula) for use in the United States should be monovalent (single strain) JN.1 vaccines to more closely match cu

      6/7/24 3:46:22 PM ET
      $GERN
      $SRAX
      $SNAP
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Advertising
      Consumer Discretionary
    • FDA Approval for RYTELO issued to GERON CORP

      Submission status for GERON CORP's drug RYTELO (ORIG-1) with active ingredient IMETELSTAT has changed to 'Approval' on 06/06/2024. Application Category: NDA, Application Number: 217779, Application Classification: Type 1 - New Molecular Entity

      6/7/24 12:36:59 PM ET
      $GERN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • March 22, 2024 - FDA Roundup: March 22, 2024

      For Immediate Release: March 22, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA issued an emergency use authorization for Pemgarda (pemivibart) for the pre-exposure prophylaxis (prevention) of COVID-19 in certain adults and adolescents (12 years of age and older weighing at least 40 kilograms [about 88 pounds]).  Pemgarda is

      3/22/24 5:02:42 PM ET
      $SNAP
      $SRAX
      Computer Software: Programming Data Processing
      Technology
      Advertising
      Consumer Discretionary

    $GERN
    $SRAX
    $SNAP
    SEC Filings

    See more
    • SEC Form 10-Q filed by Geron Corporation

      10-Q - GERON CORP (0000886744) (Filer)

      5/7/25 4:06:43 PM ET
      $GERN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Geron Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - GERON CORP (0000886744) (Filer)

      5/7/25 7:05:42 AM ET
      $GERN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 filed by Snap Inc.

      S-8 - Snap Inc (0001564408) (Filer)

      5/1/25 4:11:12 PM ET
      $SNAP
      Computer Software: Programming Data Processing
      Technology

    $GERN
    $SRAX
    $SNAP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Geron Corporation

      SC 13G/A - GERON CORP (0000886744) (Subject)

      11/14/24 5:46:12 PM ET
      $GERN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Geron Corporation

      SC 13G/A - GERON CORP (0000886744) (Subject)

      11/14/24 9:31:41 AM ET
      $GERN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Geron Corporation

      SC 13G - GERON CORP (0000886744) (Subject)

      11/14/24 6:25:29 AM ET
      $GERN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GERN
    $SRAX
    $SNAP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Geron downgraded by Scotiabank with a new price target

      Scotiabank downgraded Geron from Sector Outperform to Sector Perform and set a new price target of $1.50

      5/8/25 8:26:41 AM ET
      $GERN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Geron downgraded by B. Riley Securities with a new price target

      B. Riley Securities downgraded Geron from Buy to Neutral and set a new price target of $2.00 from $3.50 previously

      2/27/25 6:20:37 AM ET
      $GERN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Geron downgraded by H.C. Wainwright

      H.C. Wainwright downgraded Geron from Buy to Neutral

      2/26/25 12:09:25 PM ET
      $GERN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GERN
    $SRAX
    $SNAP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Technology Officer Murphy Robert C. gifted 302,084 shares and sold $8,025,400 worth of shares (1,000,000 units at $8.03), decreasing direct ownership by 2% to 54,215,224 units (SEC Form 4)

      4 - Snap Inc (0001564408) (Issuer)

      5/5/25 8:00:03 PM ET
      $SNAP
      Computer Software: Programming Data Processing
      Technology
    • General Counsel O'Sullivan Michael J. sold $185,875 worth of shares (24,000 units at $7.74) (SEC Form 4)

      4 - Snap Inc (0001564408) (Issuer)

      5/1/25 7:00:07 PM ET
      $SNAP
      Computer Software: Programming Data Processing
      Technology
    • General Counsel O'Sullivan Michael J. sold $206,386 worth of shares (24,000 units at $8.60) (SEC Form 4)

      4 - Snap Inc (0001564408) (Issuer)

      4/2/25 7:00:04 PM ET
      $SNAP
      Computer Software: Programming Data Processing
      Technology

    $GERN
    $SRAX
    $SNAP
    Financials

    Live finance-specific insights

    See more

    $GERN
    $SRAX
    $SNAP
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Geron Corporation Reports First Quarter 2025 Financial Results and Recent Business Highlights

      Reported $39.4 million in RYTELO® (imetelstat) net product revenue in Q1 2025; revenue impacted by inventory dynamics, with Q1 demand relatively flat Granted marketing authorization of RYTELO by the European Commission (EC); planning for commercial launch in select EU countries 2026 Reached approximately 85% enrollment in the Phase 3 IMpactMF clinical trial for treatment of relapsed/refractory myelofibrosis; interim analysis remains expected in 2H 2026 Company to host conference call and webcast today, May 7 at 8:00 a.m. ET Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today reported financial

      5/7/25 7:00:00 AM ET
      $GERN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Snap Inc. Announces First Quarter 2025 Financial Results

      First quarter revenue increased 14% year-over-year to $1,363 million Daily Active Users increased 9% year-over-year to 460 million Net loss improved 54% year-over-year to $140 million Adjusted EBITDA improved 137% year-over-year to $108 million Snap Inc. (NYSE:SNAP) today announced financial results for the quarter ended March 31, 2025. "We surpassed an important milestone in Q1, with our community growing to over 900 million monthly active users," said Evan Spiegel, CEO. "Quarterly revenue increased 14% year-over-year, driven by the progress we have made with our direct-response advertising solutions, continued momentum in driving performance for small and medium sized businesses, and

      4/29/25 4:10:00 PM ET
      $SNAP
      Computer Software: Programming Data Processing
      Technology
    • Snap Inc. Announces Date of First Quarter 2025 Results Conference Call

      Snap Inc. (NYSE:SNAP) will hold its quarterly conference call to discuss first quarter 2025 financial results on Tuesday, April 29, 2025 at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time). A live webcast and replay of the conference call will be accessible on Snap Inc.'s Investor Relations website for at least 90 days at: http://investor.snap.com. About Snap Inc. Snap Inc. is a technology company. We believe the camera presents the greatest opportunity to improve the way people live and communicate. We contribute to human progress by empowering people to express themselves, live in the moment, learn about the world, and have fun together. For more information, visit snap.com. View source

      4/2/25 4:10:00 PM ET
      $SNAP
      Computer Software: Programming Data Processing
      Technology
    • Geron Corporation Reports First Quarter 2025 Financial Results and Recent Business Highlights

      Reported $39.4 million in RYTELO® (imetelstat) net product revenue in Q1 2025; revenue impacted by inventory dynamics, with Q1 demand relatively flat Granted marketing authorization of RYTELO by the European Commission (EC); planning for commercial launch in select EU countries 2026 Reached approximately 85% enrollment in the Phase 3 IMpactMF clinical trial for treatment of relapsed/refractory myelofibrosis; interim analysis remains expected in 2H 2026 Company to host conference call and webcast today, May 7 at 8:00 a.m. ET Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today reported financial

      5/7/25 7:00:00 AM ET
      $GERN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Snap Inc. Announces First Quarter 2025 Financial Results

      First quarter revenue increased 14% year-over-year to $1,363 million Daily Active Users increased 9% year-over-year to 460 million Net loss improved 54% year-over-year to $140 million Adjusted EBITDA improved 137% year-over-year to $108 million Snap Inc. (NYSE:SNAP) today announced financial results for the quarter ended March 31, 2025. "We surpassed an important milestone in Q1, with our community growing to over 900 million monthly active users," said Evan Spiegel, CEO. "Quarterly revenue increased 14% year-over-year, driven by the progress we have made with our direct-response advertising solutions, continued momentum in driving performance for small and medium sized businesses, and

      4/29/25 4:10:00 PM ET
      $SNAP
      Computer Software: Programming Data Processing
      Technology
    • Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      Geron Corporation (NASDAQ:GERN), a commercial stage biopharmaceutical company, today reported that it has granted equity awards covering an aggregate of 1,551,000 shares of its common stock, consisting of stock options to purchase an aggregate of 1,034,000 shares of common stock and restricted stock units ("RSUs") representing an aggregate of 517,000 shares of common stock, to twelve newly hired employees as an inducement material to their acceptance of employment with the Company. The stock options and RSUs were granted on April 17, 2025. The stock options have an exercise price of $1.27 per share, which is equal to the closing price of Geron common stock on the grant date, have a 10-year

      4/18/25 4:30:00 PM ET
      $GERN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GERN
    $SRAX
    $SNAP
    Leadership Updates

    Live Leadership Updates

    See more
    • Geron Corporation Announces Departure of Chief Executive Officer

      Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that John "Chip" A. Scarlett, M.D., President, Chief Executive Officer and Chairman, will depart the company on March 31, 2025. While a search for a new Chief Executive Officer with significant commercial experience is underway, the Board of Directors has appointed Board member Dawn Carter Bir as Interim President and Chief Executive Officer, effective immediately. Additionally, Elizabeth G. O'Farrell has been appointed as Chair of the Board. "It has been an honor to serve Geron over the last 14 years and participate in the development

      3/11/25 4:02:00 PM ET
      $GERN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Later Announces Partnership with Snap Inc. Delivering the Industry's Most Comprehensive Integration for Social and Influencer Marketing

      BOSTON, Feb. 27, 2025 /PRNewswire/ -- Later, a leader in influencer marketing and social media management software and services, today announces a partnership with Snap Inc.  (NYSE:SNAP), that redefines creator partnerships and content publishing on Snapchat. The collaboration introduces two key capabilities through Snapchat's APIs: discovery of creator profiles within Later's influencer marketing platform, and automated content scheduling and posting through Later's social media management platform. Later is the first to integrate both Snapchat's Public Profile API (organic posting) and Creator Discovery API within the same platform.

      2/27/25 9:00:00 AM ET
      $SNAP
      Computer Software: Programming Data Processing
      Technology
    • Geron Corporation Announces Appointment of Joseph Eid, M.D. as Executive Vice President, Research and Development

      Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced the appointment of Joseph Eid, M.D. as Executive Vice President, Research and Development, effective today, November 11, 2024. In this role, Dr. Eid will lead our Research and Development organization comprised of medical, clinical, and safety/pharmacovigilance teams and be responsible for driving innovative medical and scientific strategies that support RYTELO™ commercially and sustain important research and development opportunities for Geron. Dr. Eid has more than two decades of medical affairs, clinical development, and drug life-cy

      11/11/24 4:30:00 PM ET
      $GERN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GERN
    $SRAX
    $SNAP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP, Chief Legal Officer Samuels Scott Alan bought $24,150 worth of shares (15,000 units at $1.61), increasing direct ownership by 128% to 26,682 units (SEC Form 4)

      4 - GERON CORP (0000886744) (Issuer)

      3/3/25 6:01:08 AM ET
      $GERN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chairman, President and CEO Scarlett John A bought $22,062 worth of shares (12,500 units at $1.76) (SEC Form 4)

      4 - GERON CORP (0000886744) (Issuer)

      3/3/25 6:01:06 AM ET
      $GERN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP, Chief Commercial Officer Ziegler James bought $160,000 worth of shares (100,000 units at $1.60) (SEC Form 4)

      4 - GERON CORP (0000886744) (Issuer)

      3/3/25 6:01:05 AM ET
      $GERN
      Biotechnology: Pharmaceutical Preparations
      Health Care